Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Immutep Ltd

Healthcare AU IMM

0.395AUD
-(-%)

Last update at 2026-03-09T23:00:00Z

Day Range

0.400.40
LowHigh

52 Week Range

0.220.47
LowHigh

Fundamentals

  • Previous Close 0.40
  • Market Cap576.99M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-82.39028M
  • Revenue TTM7.92M
  • Revenue Per Share TTM0.005
  • Gross Profit TTM -74.77984M
  • Diluted EPS TTM-0.06

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -61.43417M -42.71700M -39.89635M -32.21079M -29.90259M
Minority interest - - - - -
Net income -61.43417M -42.71700M -39.89635M -32.21083M -29.90262M
Selling general administrative 8.64M 8.85M 8.68M 7.21M 6.28M
Selling and marketing expenses - - - - -
Gross profit -56.36676M -37.70500M - 0.17M -
Reconciled depreciation - - - 3.00M -
Ebit -65.01126M -46.55700M -41.43131M -33.93755M -19.56058M
Ebitda -62.87685M -44.54400M - -31.87409M -20.72271M
Depreciation and amortization 2.13M 2.01M - 2.06M -1.16213M
Non operating income net other - - - - -
Operating income -126.42180M -88.10400M -40.63135M -33.93755M -19.56058M
Other operating expenses 131.47M 91.95M - 34.01M 19.66M
Interest expense 0.04M 0.03M 0.02M 0.09M 0.00983M
Tax provision - 0.00000M 0.00000M 0.00005M 0.00003M
Interest income 3.73M 3.88M 0.74M 0.33M 0.11M
Net interest income - 3.85M 0.92M 0.19M 0.10M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - 0.00003M 0.00003M
Total revenue 5.04M 3.84M 1.13M 0.17M 0.42M
Total operating expenses 70.06M 50.40M 41.43M 34.01M 19.66M
Cost of revenue 61.41M 41.55M - - -
Total other income expense net 64.99M 45.39M 0.62M 1.73M -10.34201M
Discontinued operations - - - - -
Net income from continuing ops - -42.71663M -39.89635M -46.82423M -29.90262M
Net income applicable to common shares -61.43417M -42.71663M -39.89635M -32.21083M -29.90262M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 156.98M 201.58M 147.45M 102.17M 82.03M
Intangible assets 7.09M 8.13M 9.38M 10.44M 12.74M
Earning assets - - - - -
Other current assets 19.40M - 0.05M 3.55M 2.17M
Total liab 13.35M 12.06M 10.98M 8.09M 8.76M
Total stockholder equity 143.64M 189.52M 136.47M 94.08M 73.27M
Deferred long term liab - - - - -
Other current liab 5.91M - 4.14M 3.37M 3.31M
Common stock 535.07M - 446.27M 367.41M 313.42M
Capital stock - 542.11M 446.27M 534.09M 313.42M
Retained earnings -444.08132M -382.64716M -339.93053M -302.33521M -274.64222M
Other liab - - 0.16M 0.12M 0.81M
Good will 0.11M 0.11M 0.11M 0.11M 0.11M
Other assets - - 2.52M 0.50M 0.45M
Cash 67.41M 161.79M 123.42M 80.00M 60.13M
Cash and equivalents - - 3.59M 0.30M 8.28M
Total current liabilities 12.76M 10.49M 9.77M 6.41M 5.34M
Current deferred revenue - - - - -
Net debt -65.78303M - -122.18945M -78.26131M -57.31301M
Short term debt 1.31M - 0.19M 0.17M 0.21M
Short long term debt - - - - -
Short long term debt total 1.63M - 1.23M 1.73M 2.82M
Other stockholder equity - - 6.43M 5.43M 44.15M
Property plant equipment - - 0.47M 0.31M 0.31M
Total current assets 149.10M 191.35M 134.97M 90.81M 68.42M
Long term investments - - - - -
Net tangible assets - - 126.98M 83.52M 60.42M
Short term investments 62.28M 20.09M - - -
Net receivables 0.00746M 0.00524M 7.97M 8.37M 6.12M
Long term debt - 0.96M 0.84M 2.11M 2.53M
Inventory - - - -1.10832M -
Accounts payable 5.53M 3.79M 5.45M 2.87M 1.82M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 52.65M - 30.13M 29.00M 34.49M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.12M - 2.52M 0.50M 0.45M
Deferred long term asset charges - - - - -
Non current assets total 7.89M 10.23M 12.48M 11.36M 13.61M
Capital lease obligations - 0.63M 0.39M 0.41M 0.29M
Long term debt total - - 1.04M 1.56M 2.61M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments - -21.01868M -0.03100M -0.04500M -0.02400M
Change to liabilities - - 3.27M 1.44M 1.38M
Total cashflows from investing activities -38.53321M -21.01868M -0.08274M -0.02291M -0.01560M
Net borrowings - -0.22649M -0.21197M -0.22254M -0.21438M
Total cash from financing activities -0.52512M 95.18M 76.04M 50.33M 52.68M
Change to operating activities - - -0.90011M -0.74727M -0.54342M
Net income -61.43417M -42.71663M -39.89635M -32.21083M -29.90262M
Change in cash -94.38193M 38.37M 43.42M 19.40M 34.27M
Begin period cash flow 161.79M 123.42M 80.00M 60.59M 26.32M
End period cash flow 67.41M 161.79M 123.42M 80.00M 60.59M
Total cash from operating activities -62.04971M -34.82123M -35.88300M -30.22975M -17.64034M
Issuance of capital stock - 100.24M 80.08M 52.98M 43.31M
Depreciation 2.39M - 2.06M 2.06M 2.07M
Other cashflows from investing activities -0.22541M -0.90315M - - -
Dividends paid - - 0.00000M 0.00000M -
Change to inventory - - - - -
Change to account receivables -2.51809M 0.60M -1.60770M -2.24938M -2.83054M
Sale purchase of stock - - 80.08M 52.98M 54.57M
Other cashflows from financing activities - -4.82897M -3.85600M -2.42715M 9.59M
Change to netincome - - 1.71M 1.48M 12.18M
Capital expenditures 0.05M 0.93M 0.05M 0.02M 0.02M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -8.54296M 3.99M 4.66M -1.56119M 1.75M
Stock based compensation 1.16M - - 1.49M -
Other non cash items 4.37M -38.81618M - -0.00804M 29.90M
Free cash flow -62.09548M -35.75360M -35.93000M -30.25267M -17.65594M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IMM
Immutep Ltd		 - -% 0.40 - 7.20 72.83 3.89 994.70 -4.4207
CSL
CSL Ltd		 -1.98 1.37% 142.58 16.70 19.49 4.61 2.68 3.87 11.63
TLX
TELIX Pharmaceuticals Ltd		 -0.24 2.18% 10.76 - 1000.00 4.25 5.68 3.34 76.39
MSB
Mesoblast Ltd		 0.02 0.92% 2.20 - 454.55 43.02 3.19 28.08 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.2 1.57% 12.55 53.70 45.66 24.19 4.61 19.56 57.40

Reports Covered

Stock Research & News

View All

Profile

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.

Immutep Ltd

Australia Square, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Mr. Marc Voigt CEO, MD, CFO, Chief Bus. Officer & Exec. Director 1973
Ms. Deanne Miller LLB COO, Gen. Counsel & Joint Company Sec. 1977
Dr. Frederic Triebel M.D., Ph.D. Chief Scientific Officer, Chief Medical Officer & Exec. Director 1955
Ms. Indira Naidu Joint Company Sec. NA
Mr. Christian Mueller Director of Clinical Devel. & Regulatory Affairs NA
Mr. Shengfei Fang Fin. Director & Assistant Company Sec. NA
Mr. Marc Voigt CEO, MD, CFO, Chief Business Officer & Executive Director 1973
Ms. Deanne Miller LLB COO, General Counsel & Joint Company Secretary 1977
Dr. Frederic Triebel M.D., Ph.D. Chief Scientific Officer & Executive Director 1955
Mr. Marc Voigt CEO, MD, CFO, Chief Business Officer & Executive Director 1973

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.